Bristol Myers Squibb (CELG-RI) Non Operating Interest Expenses (2012 - 2013)
Bristol Myers Squibb's (CELG-RI) quarterly Non Operating Interest Expenses came in at $50.0 million in Q1 2013, up 19.05% year-over-year from $42.0 million in Q1 2012, and up 19.05% quarter-over-quarter from $42.0 million in Q1 2012.
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) Non Operating Interest Expenses (2012 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Non Operating Interest Expenses for 2 consecutive years, with $50.0 million the latest figure, recorded in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Bristol Myers Squibb | 234.63 Mn | -10.83 Bn | 9.25 Bn | - |